Dominic V. Simone

Array ( [id] => 18709534 [patent_doc_number] => 20230332153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/059561 [patent_app_country] => US [patent_app_date] => 2022-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18469213 [patent_doc_number] => 20230203497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES [patent_app_type] => utility [patent_app_number] => 18/053771 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18324116 [patent_doc_number] => 20230122244 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS [patent_app_type] => utility [patent_app_number] => 17/982819 [patent_app_country] => US [patent_app_date] => 2022-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17982819 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449477 [patent_doc_number] => 20230190753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BETA-CATENIN-ASSOCIATED DISEASE OR DISORDER [patent_app_type] => utility [patent_app_number] => 18/050760 [patent_app_country] => US [patent_app_date] => 2022-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786413 [patent_doc_number] => 20230374516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => USE OF NON-CODING RNA SNHG17 AS BIOMARKER AND THERAPEUTIC TARGET [patent_app_type] => utility [patent_app_number] => 18/048451 [patent_app_country] => US [patent_app_date] => 2022-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20826547 [patent_doc_number] => 12680104 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-14 [patent_title] => DNA aptamers for eosinophil peroxidase detection [patent_app_type] => utility [patent_app_number] => 17/966575 [patent_app_country] => US [patent_app_date] => 2022-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 33 [patent_no_of_words] => 8264 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17966575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18583174 [patent_doc_number] => 20230265434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => GENE CONSTRUCTS FOR SILENCING ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/961097 [patent_app_country] => US [patent_app_date] => 2022-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17961097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18452005 [patent_doc_number] => 20230193284 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => TRANSMEMBRANE SERINE PROTEASE 2 (TMPRSS2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/956884 [patent_app_country] => US [patent_app_date] => 2022-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68087 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17956884 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18299271 [patent_doc_number] => 20230108957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors [patent_app_type] => utility [patent_app_number] => 17/936715 [patent_app_country] => US [patent_app_date] => 2022-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18886 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109895 [patent_doc_number] => 20230002775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => METHOD OF TREATING CANCER AND METHOD OF SENSITIZING CANCER CELLS TO THE ACTION OF CHEMOTHERAPEUTIC AGENTS VIA GROWTH HORMONE RECEPTOR ANTAGONISTS OR KNOCK DOWN [patent_app_type] => utility [patent_app_number] => 17/943442 [patent_app_country] => US [patent_app_date] => 2022-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22872 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17943442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18267982 [patent_doc_number] => 20230089224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => TARGETED THERAPY COMPOSITION AND ITS USE FOR SUPPRESSING BREAST CANCER CELL PROLIFERATION, MIGRATION OR INVASION [patent_app_type] => utility [patent_app_number] => 17/930136 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20527488 [patent_doc_number] => 12545914 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/823980 [patent_app_country] => US [patent_app_date] => 2022-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 61772 [patent_no_of_claims] => 84 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468803 [patent_doc_number] => 20230203085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => MULTI-CONJUGATES COMPRISING MULTIPLE LIGANDS [patent_app_type] => utility [patent_app_number] => 17/901674 [patent_app_country] => US [patent_app_date] => 2022-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4474 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17901674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986461 [patent_doc_number] => 20240058430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => TRANSIENT EXPRESSION SYSTEM FOR RNA, FOR VACCINATION [patent_app_type] => utility [patent_app_number] => 17/818548 [patent_app_country] => US [patent_app_date] => 2022-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077780 [patent_doc_number] => 20220403392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => APTAMER NANOFIBERS AND KILL-SWITCHES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/816273 [patent_app_country] => US [patent_app_date] => 2022-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18312943 [patent_doc_number] => 20230116843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => POLYNUCLEOTIDES ENCODING TETHERED INTERLEUKIN-12 (IL12) POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/875887 [patent_app_country] => US [patent_app_date] => 2022-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111701 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17875887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18150295 [patent_doc_number] => 20230024153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID [patent_app_type] => utility [patent_app_number] => 17/815473 [patent_app_country] => US [patent_app_date] => 2022-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34149 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19449213 [patent_doc_number] => 20240309343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => RNA expression modulating or editing method via regulation of Cas13 protein [patent_app_type] => utility [patent_app_number] => 17/907472 [patent_app_country] => US [patent_app_date] => 2022-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18462968 [patent_doc_number] => 11687256 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-27 [patent_title] => Methods of using OX40 ligand encoding polynucleotides [patent_app_type] => utility [patent_app_number] => 17/858664 [patent_app_country] => US [patent_app_date] => 2022-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 61 [patent_no_of_words] => 69005 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17858664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19326167 [patent_doc_number] => 12043833 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-23 [patent_title] => Targeted compositions [patent_app_type] => utility [patent_app_number] => 17/854575 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 33576 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17854575 [rel_patent_id] =>[rel_patent_doc_number] =>)